These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11009218)

  • 41. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
    Lindgren HS; Ohlin KE; Cenci MA
    Neuropsychopharmacology; 2009 Nov; 34(12):2477-88. PubMed ID: 19606087
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Restorative effects of glutamate antagonists in experimental parkinsonism.
    Archer T; Palomo T; Fredriksson A
    Amino Acids; 2002; 23(1-3):71-85. PubMed ID: 12373521
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
    Spinnewyn B; Charnet C; Cornet S; Roubert V; Chabrier PE; Auguet M
    Fundam Clin Pharmacol; 2011 Oct; 25(5):608-18. PubMed ID: 21077938
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
    Grégoire L; Jourdain VA; Townsend M; Roach A; Di Paolo T
    Parkinsonism Relat Disord; 2013 May; 19(5):508-14. PubMed ID: 23402994
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
    Savola JM; Hill M; Engstrom M; Merivuori H; Wurster S; McGuire SG; Fox SH; Crossman AR; Brotchie JM
    Mov Disord; 2003 Aug; 18(8):872-83. PubMed ID: 12889076
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
    Smith LA; Jackson MJ; Al-Barghouthy G; Rose S; Kuoppamaki M; Olanow W; Jenner P
    Mov Disord; 2005 Mar; 20(3):306-14. PubMed ID: 15490461
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
    Samadi P; Grégoire L; Hadj Tahar A; Di Paolo T; Rouillard C; Bédard PJ
    Neuropharmacology; 2005 Aug; 49(2):165-73. PubMed ID: 15996565
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.
    Badawi GA; Abd El Fattah MA; Zaki HF; El Sayed MI
    Neurotox Res; 2019 Apr; 35(3):635-653. PubMed ID: 30673988
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comments on the NMDA antagonist memantine.
    Fischhof PK
    Methods Find Exp Clin Pharmacol; 2003 Apr; 25(3):173. PubMed ID: 12743619
    [No Abstract]   [Full Text] [Related]  

  • 51. The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations.
    Spieker S; Löschmann PA; Klockgether T
    Mov Disord; 1999 May; 14(3):517-9. PubMed ID: 10348483
    [No Abstract]   [Full Text] [Related]  

  • 52. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates.
    Johnston TH; Fox SH; Piggott MJ; Savola JM; Brotchie JM
    Mov Disord; 2010 Oct; 25(13):2084-93. PubMed ID: 20824735
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.
    Ruiz-DeDiego I; Mellstrom B; Vallejo M; Naranjo JR; Moratalla R
    Biol Psychiatry; 2015 Jan; 77(2):95-105. PubMed ID: 24857398
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients: a 3-year follow-up study.
    Contin M; Riva R; Martinelli P; Albani F; Baruzzi A
    Clin Neuropharmacol; 1997 Oct; 20(5):409-18. PubMed ID: 9331517
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Are anti-dementia drugs worthwhile?].
    Lang CJ
    MMW Fortschr Med; 2007 Sep; 149 Suppl 3():85-9. PubMed ID: 17955784
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
    Zubair M; Jackson MJ; Tayarani-Binazir K; Stockwell KA; Smith LA; Rose S; Olanow W; Jenner P
    Exp Neurol; 2007 Dec; 208(2):177-84. PubMed ID: 17935716
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
    Papa SM; Chase TN
    Ann Neurol; 1996 May; 39(5):574-8. PubMed ID: 8619541
    [TBL] [Abstract][Full Text] [Related]  

  • 60. L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
    Pinna A; Bonaventura J; Farré D; Sánchez M; Simola N; Mallol J; Lluís C; Costa G; Baqi Y; Müller CE; Cortés A; McCormick P; Canela EI; Martínez-Pinilla E; Lanciego JL; Casadó V; Armentero MT; Franco R
    Exp Neurol; 2014 Mar; 253():180-91. PubMed ID: 24412491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.